• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

    6/27/25 7:35:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials
    Get the next $DHR alert in real time by email

    WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer.

    This appointment marks a pivotal step in Danaher's digital transformation and its ambition to lead the next era of innovation in life sciences and diagnostics. Under Dr. Stumpe's leadership, Danaher will seek to accelerate the integration of AI across its global businesses—unlocking new levels of scientific discovery, operational efficiency and clinical impact.

    "Danaher is committed to building a future where science, data and technology work seamlessly to improve human health," said Rainer Blair. "Martin is a visionary technology leader with a deep understanding of how AI and data can transform healthcare. His track record of innovation, combined with his passion for applying advanced technologies to improve human health, makes him the ideal leader to further accelerate our digital transformation."

    Dr. Stumpe joined Danaher in 2024, as Chief Data and AI Officer, from Tempus, where he spearheaded AI initiatives aiming to make precision medicine a reality. Prior to Tempus, he founded the Cancer Pathology project at Google – which aimed to enhance the accuracy of cancer detection and grading using AI techniques – and was part of the Kepler team at NASA's Ames Research Center. Dr. Stumpe holds a Ph.D. in Computational & Theoretical Physics from the Max Planck Institute for Biophysical Chemistry in Germany.

    ABOUT DANAHER

    Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

    FORWARD-LOOKING STATEMENTS

    Statements in this release that are not strictly historical, including the statements regarding Danaher's ambitions with respect to AI and digital transformation and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of tariffs and related actions recently implemented by the U.S. and other countries, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the healthcare industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the healthcare industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory changes or uncertainty and military conflicts), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2024 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the first quarter of 2025. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

    Cision View original content:https://www.prnewswire.com/news-releases/danaher-appoints-martin-stumpe-as-chief-technology-and-ai-officer-302492783.html

    SOURCE Danaher Corporation

    Get the next $DHR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DHR

    DatePrice TargetRatingAnalyst
    4/10/2025$205.00Equal Weight → Overweight
    Barclays
    3/21/2025$260.00Neutral → Buy
    Goldman
    3/14/2025$260.00Hold → Buy
    Stifel
    2/3/2025Outperform → Mkt Perform
    Raymond James
    12/23/2024Sector Perform
    Scotiabank
    12/19/2024$275.00Buy
    Guggenheim
    12/13/2024$290.00Neutral → Buy
    BofA Securities
    10/31/2024$285.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $DHR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

      WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer. This appointment marks a pivotal step in Danaher's digital transformation and its ambition to lead the next era of innovation in life sciences and diagnostics. Under Dr. Stumpe's leadership, Danaher will seek to accelerate the integration of AI across its global businesses—unlocking new levels of scientific discovery, operational efficiency and clinical impact. "Danaher i

      6/27/25 7:35:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

      WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021. With this expanded role, he will become an executive officer of Danaher and will continue reporting to Rainer Blair, President and Chief Executive Officer. "Greg has played a pivotal role in advancing our Life Sciences Innovations Group over the past f

      6/27/25 7:30:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Schedules Second Quarter 2025 Earnings Conference Call

      WASHINGTON, June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You

      6/17/25 4:30:00 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Danaher upgraded by Barclays with a new price target

      Barclays upgraded Danaher from Equal Weight to Overweight and set a new price target of $205.00

      4/10/25 8:28:29 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher upgraded by Goldman with a new price target

      Goldman upgraded Danaher from Neutral to Buy and set a new price target of $260.00

      3/21/25 8:01:35 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher upgraded by Stifel with a new price target

      Stifel upgraded Danaher from Hold to Buy and set a new price target of $260.00

      3/14/25 7:34:47 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Milosevich Gregory M claimed ownership of 4,455 shares (SEC Form 3)

      3 - DANAHER CORP /DE/ (0000313616) (Issuer)

      7/1/25 5:00:51 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Director Stevens Raymond C was granted 577 shares, increasing direct ownership by 5% to 12,361 units (SEC Form 4)

      4 - DANAHER CORP /DE/ (0000313616) (Issuer)

      5/19/25 5:02:20 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Director Spoon Alan G was granted 577 shares, increasing direct ownership by 0.48% to 121,308 units (SEC Form 4)

      4 - DANAHER CORP /DE/ (0000313616) (Issuer)

      5/19/25 5:02:10 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Leadership Updates

    Live Leadership Updates

    See more
    • Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

      WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer. This appointment marks a pivotal step in Danaher's digital transformation and its ambition to lead the next era of innovation in life sciences and diagnostics. Under Dr. Stumpe's leadership, Danaher will seek to accelerate the integration of AI across its global businesses—unlocking new levels of scientific discovery, operational efficiency and clinical impact. "Danaher i

      6/27/25 7:35:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

      WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021. With this expanded role, he will become an executive officer of Danaher and will continue reporting to Rainer Blair, President and Chief Executive Officer. "Greg has played a pivotal role in advancing our Life Sciences Innovations Group over the past f

      6/27/25 7:30:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Announces Appointment of Charles Lamanna to Danaher Board

      WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Committee. Mr. Lamanna is currently Corporate Vice President, Business & Industry Copilot at Microsoft (NASDAQ:MSFT), where he drives product innovation in AI-powered business applications, low-code platforms, and autonomous agents. He oversees the design, product development, and engineering of some of Microsoft's most transformative technologies, including Power Platform, Dynamics 365, and Copilot Studio. Prior to that, Mr. Lamanna was the founder and CEO of MetricsHub, one of the first public cloud

      2/20/25 4:45:00 PM ET
      $DHR
      $MSFT
      Industrial Machinery/Components
      Industrials
      Computer Software: Prepackaged Software
      Technology

    $DHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

      SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

      2/9/23 11:16:32 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

      SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

      2/9/22 3:43:35 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13D/A filed by Danaher Corporation (Amendment)

      SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)

      11/2/21 9:29:29 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    SEC Filings

    See more
    • SEC Form 11-K filed by Danaher Corporation

      11-K - DANAHER CORP /DE/ (0000313616) (Filer)

      6/17/25 8:19:40 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • SEC Form SD filed by Danaher Corporation

      SD - DANAHER CORP /DE/ (0000313616) (Filer)

      5/12/25 4:39:59 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - DANAHER CORP /DE/ (0000313616) (Filer)

      5/8/25 4:36:17 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Financials

    Live finance-specific insights

    See more
    • Danaher Schedules Second Quarter 2025 Earnings Conference Call

      WASHINGTON, June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You

      6/17/25 4:30:00 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Announces Quarterly Dividend

      WASHINGTON, May 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and h

      5/6/25 4:15:00 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Reports First Quarter 2025 Results

      WASHINGTON, April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings were $1.0 billion, or $1.32 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.88.Revenues decreased 1.0% to $5.7 billion and non-GAAP core revenue was flat year-over-year.Operating cash flow was $1.3 billion and non-GAAP free cash flow was $1.1 billion.Rainer M. Blair, President and Chief Executive Officer, stated, "Revenue, earnings, and cash flow exceeded our expectations in the first quarter–highlighted by continued momentum in bioprocessing and better-

      4/22/25 6:00:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials